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a  b  s  t  r  a  c  t
Stereotactic body radiotherapy (SBRT) has developed over the last few years for the treatment
of  primary and metastatic hepatic tumors. The tumoral and adjacent peritumoral modifi-
cations caused by this radiosurgery limit the evaluation of response by anatomic imaging
and  dimensional criteria alone, such as with RECIST. This suggests that it is of interest to
also  take into account the residual enhancement and hyper metabolism of these hepatic
targets. We  have reviewed the English language literature regarding the response of hepatic
lesions treated by SBRT, and found that only seven articles were specifically concerned with
this  problem.
The response of the hepatocellular carcinoma after SBRT has been studied specifically
with multiphase enhanced CT-scan. Criteria set by the European Association of Study of
the  Liver better estimate response at each time point of follow up than RECIST does. Non-
enhancement, reflecting tumor necrosis, is additionally an early indicator of response with
extended response in time and a best non-enhancement percentage is observed at 12
months. The response after treatment by SBRT of cholangiocarcinoma has not yet generated
a  specific report.
Use of RECIST criteria is also inadequate in the evaluation of response after SBRT for
hepatic metastases. Response of liver metastases to SBRT is better assessed with a combi-
nation of size and enhancement pattern. The occurrence of a lobulated enhancement during
follow up is efficient to predict local progression in a specific, reproducible, and sensitiveway. Patients with FDG-avid hepatic metastases are also better evaluated with PET-CT and
functional criteria than routine imaging and metric evaluation alone.
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.  Background
xtra cranial stereotactic body radiotherapy (SBRT) has been
hown to be a therapeutic alternative in the ablation of pri-
ary hepatic diseases (cholangiocarcinoma, hepatocellular
arcinoma) and hepatic metastases.1,2
The morphological evaluation of this treatment by routine
maging is a problem. Indeed, the criteria of response in solid
umors (RECIST) is not applicable in the irradiated zone as
tated in the revisited RECIST guideline, except in the case of
rogressive disease.3 This is due to the compulsory early reor-
anizations of the irradiated zone which can mask a partial or
omplete response.4
This limitation of the strictly dimensional evaluation of the
epatic lesions was previously identified for other targeted
herapies or other ways of percutaneous destruction. Further
o its conference of September, 2000, the European Associa-
ion of Study of the Liver (EASL) recommended to consider
he enhancement of the viable portions after percutaneous
r endovascular treatment of hepatocellular carcinoma (HCC)
n computerized tomography (CT) and magnetic resonance
maging (MRI).5 Therefore, the RECIST guideline was modi-
ed for this particular evaluation in 2008 (mRECIST).6 Also,
hanges in CT density were usefully added to size criteria
o estimate the response to imatinib of the gastro-intestinal
tromal tumor hepatic metastases.7 The enhancement of
epatic metastases due to colorectal cancer after treatment
ith bevacizumab has also been taken into account from
009.8
Positron-emission tomography (PET) is a functional imag-
ng modality that logically claims to best evaluate the liver
reated by SBRT. Considering the limitations of anatomic
maging alone in assessing the activity of newer cancer
herapies that stabilize disease, 18F-FDG PET could be effi-
ient in such cases.9 From this perspective, standardization
s even available to improve reproducibility of the PET
esponse Criteria in Solid Tumors (PERCIST).9 Acuteness of
DG-based criteria is shown particularly in the evaluation
f patients with Non-Small Cell Lung Cancer treated with
BRT.10–14
We  bring together in this work articles of English language
iterature estimating the response of hepatic lesions treated
y SBRT.
.  Evaluation  of  response  after  SBRT  for
rimary  hepatic  tumors
are of HCC often includes local treatments such as
adiofrequency and chemoembolization, reshaping targets
nd leaving scars. This hampers the evaluation of their effi-
iency by metric criteria. Therefore, learned societies propose
riteria to estimate the viable portion enhancing during the
rterial phase of the CT or MR  imaging.5,6,15
SBRT also leads to acute tumoral change and normal tissue
egeneration which can distort a purely dimensional evalua-
ion. Herfarth et al. described in 2003 several types of early
arget modifications after SBRT, changing during follow-up.4
hese reorganizations do not cause, however, a typical arterialtherapy 2 2 ( 2 0 1 7 ) 170–175 171
enhancement of HCC as seen with multiphase CT-scanning.
Moreover, abnormal enhancement of peritumoral liver is seen
in most cases by 6 months.16,17 Nevertheless, these arterial
enhancements of healthy liver do not present a typical portal
wash out of HCC.
The criteria used in the evaluation of response to SBRT
in the management of HCC are heterogeneous in the
reported series. Certain works limit themselves to the RECIST
criteria.18–22 Other publications apply recommended EASL or
mRECIST criteria.23–27
A single article compared the RECIST and EASL criteria in
this indication. Price et al. reported in 2012 on a series of 26
patients treated for 29 CHC by SBRT by comparing the morpho-
logical evolution according to the RECIST and EASL criteria16
(Table 1). This evaluation consisted of MRI  and CT examina-
tions with dynamic injection quarterly during one year. They
observed that the RECIST criteria underestimated response
at each time point. In addition, this analysis suggested that
tumor non-enhancement, reflecting tumor necrosis, is an
early indicator of response. Best non-enhancement percent-
age is observed at 12 months. Nevertheless, a baseline pattern
of those lesions was not described in that work. We  may
suppose that only HCC with typical enhancement prior to
SBRT were included. Moreover, in the cases of mismatch
between response estimated by RECIST and EASL criteria, fur-
ther research is called for. In those cases, a gold standard will
consist ideally in a pathologic response in explanted liver.
The evolution of the local response according to mRECIST
criteria is extended in time. This aspect was studied in par-
ticular in the series published by Sanuki et al. in 2013.28 They
showed, according to mRECIST, that local CR increased over
time with a maximum 2-year local control rate of 97%. Two
delayed local relapses occurred at 1 and 3 years. The hepatic
recurrence outside the treatment volume reached the level
of 58%. Sustained follow up is, therefore, warranted until
tumor regrowth. It should be noted that only typical enhanced
lesions are studied in that cohort.
The interest of the metabolic imaging in this indication is
not demonstrated. Huang et al. aimed to determine whether
18F-FDG-PET/CT and combined 18F-FDG with contrast CT
parameter could predict tumor control.29 Even if this study
is quiet irrelevant for our issue (evaluation of response), it is of
interest to pinpoint that SUVmax could be the best indicator
regarding local control. SBRT of HCC with baseline SUVmax
below 3.2, indeed, enables a better 4y tumor control rate. Nev-
ertheless, we should remember that the sensitivity of 18F-FDG
for diagnosis of HCC is low: only 50–55%.30–32
To our knowledge, the evaluation of the response after
treatment by SBRT of cholangiocarcinoma has not generated
scientific report to this day.
3.  Evaluation  of  response  after  SBRT  for
hepatic  metastases
With the emergence of the concept of oligo-metastatic state,
techniques of focal ablation, such as SBRT, are proposed to
cure hepatic metastases.1,33,34 For the same reasons as in the
case of HCC discussed above, the evaluation of response could
be limited with RECIST criteria in these cases.
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Table 1 – Main original publications concerning evaluation of response after SBRT for liver tumors. Abbreviations:  SBRT,
stereotactic body radiotherapy; RECIST, criteria of response in solid tumors; mRECIST, modified criteria of response in
solid tumors; CT, computerized tomography; MRI, magnetic resonance imaging; PET, positron-emission tomography;
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Jarraya et al. began in 2013 by describing post-therapeutic
T transformations of secondary hepatic lesions treated with
yberknife.35 Following the example of the work by Chun
n the hepatic metastases treated by bevacizumab,8 they
escribed four types of responses according to the evolution
n size, the occurrence of a lobulated enhancement or total
ecrosis. According to that work, the use of RECIST criteria
ay be inadequate. Response of liver metastases to SBRT is
etter assessed with a combination of size and enhancement
attern.
That team continued on the same subject by focusing
n the occurrence of lobulated enhancement during the
ollow up.36 That enhancement was observed in 89% of pro-
ressive lesions, occurring before size-based progression in
alf of the cases, with a median delay of 3.2 months. The
ensitivity of Lobular Enhancement to predict progression
as 89%, and its specificity was 100%. The probability of
ocal progression-free survival at 12 months was significantly
igher for lesions without Lobular enhancement compared
ith all lesions: 0.80 (95% CI: 0.65–0.89) versus 0.69 (95% CI:
.54–0.80), respectively. The overall concordance rate between
he 2 readers in identifying lobular enhancement was 97.9%.
hat pattern appears actually efficient to predict local pro-
ression in a specific, reproducible, and rather sensitive
ay.
The cohort reported by Solanki et al. also included some
ases of hepatic metastases treated by SBRT and evaluated by
8F-FDG PET-CT.37 Even if this work was not solely dedicated to
epatic metastases, it suggested the interest of 18F-FDG PET-
T in the evaluation of response to SBRT in oligo-metastatic
isease, in particular for the recovery of patients with com-
lete response underestimated by RECIST criteria as a stable
isease.
In the same way, Stinauer et al. characterized SUV changes
f hepatic metastases after SBRT and evaluated normal tis-
ue regeneration.38 They found that SUVmax of controlled
esions decreased to 3.1, similar to median SUVmax of nor-
al  liver. The cut-off to define local control failure consisted
n SUVmax ≥ 6. Liver volume after SBRT reached its NADIR
20% less) between 3 and 6 months. It is to be noted that





Only seven original articles are dedicated to the evaluation of
response to liver after SBRT.
Response of hepatocellular carcinoma after SBRT has been
studied specifically with multiphase enhanced CT-scan. Crite-
ria of the European Association of Study of the Liver better
estimates response at each time point of follow up than
RECIST does. Non-enhancement is additionally an early indi-
cator of response with extended response in time and the best
non-enhancement percentage is observed at 12 months. The
limitations of RECIST criteria remain unresolved for targets
with atypical enhancement. The response after treatment by
SBRT of cholangiocarcinoma has not yet generated a specific
report.
Use of RECIST criteria is also inadequate in the evalua-
tion of response after SBRT for hepatic metastases. Response
of liver metastases to SBRT is better assessed with a com-
bination of size and enhancement pattern. The occurrence
of a lobulated enhancement during follow-up is useful to
predict local progression in a specific, reproducible, and sen-
sitive way. Patients with FDG-avid hepatic metastases may
also be evaluated with 18F-FDG PET-CT and functional crite-
ria. Surprisingly, no specific evaluation with MRI functional
parameters, such as diffusion-weighted imaging has been pro-
posed on that topic.
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